Jun 2026 (Q2 FY26) — Aug 6, 2026
REGENXBIO Q2 FY26 — Late-Stage Pipeline Progress & Strengthened Financial Position
Read the full callREGENXBIO (RGNX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
REGENXBIO earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 108 | +405.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 27.1 | +323.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 22.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.16 +4.07% · +$0.28
Performance −36.4% 1Y
1Y: $11.25 on 14 Oct 2025 → $7.16. High $15.98 (22 Jan 2026), low $5.65 (18 May 2026).
- Previous close
- $6.88
- 52-week range
- $5.65 – $15.98
- One year
- −41.79%
Overview
- Symbol
- RGNX
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
REGENXBIO earnings calls (RGNX)
Financials
What the filings say
Net profit, year on year: +132% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 21 | 89 | 21 | 30 | 30 | 6 | 108 |
| Expenses | 86 | 73 | 77 | 85 | 82 | 88 | 90 | 79 |
| Operating profit | -62 | -51 | 12 | -63 | -52 | -58 | -83 | 29 |
| Operating margin | −256.6% | −242.1% | 13.6% | −296.3% | −176.3% | −190.0% | −1304.0% | 27.1% |
| Other income | 2 | 0 | -6 | -8 | -10 | -10 | -7 | -7 |
| Interest | 1 | 9 | 9 | 11 | 13 | 12 | 9 | 8 |
| Net profit | -60 | -51 | 6 | -71 | -62 | -67 | -90 | 23 |
| EPS ($ per share) | -1.17 | — | 0.12 | -1.38 | -1.20 | — | -1.72 | 0.43 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -83 | -178 | -289 | -161 | -442 | -705 | -932 | -1,126 |
| Total liabilities | 35 | 48 | 330 | 350 | 317 | 262 | 206 | 350 |
| Fixed assets | 29 | 29 | 56 | 132 | 142 | 132 | 118 | 105 |
| Investments | 244 | 227 | 137 | 112 | 268 | 241 | 177 | 196 |
| Total assets | 544 | 498 | 708 | 1,114 | 833 | 574 | 466 | 453 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 105 | -108 | -54 | 219 | -207 | -218 | -173 | -124 |
| Cash from investing | -279 | 94 | 123 | -407 | -12 | 191 | 103 | -16 |
| Cash from financing | 204 | 8 | 200 | 195 | -29 | -35 | 93 | 117 |
| Net cash flow | 30 | -6 | 269 | 7 | -248 | -62 | 23 | -23 |
| Capital expenditure | -13 | -12 | -27 | -84 | -31 | -10 | -2 | -2 |
| Free cash flow | 91 | -119 | -81 | 135 | -238 | -228 | -176 | -126 |
Insider filings
39 filings between Dec 31, 2025 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
$949.4K
2 purchases by 1 insider
Sales
$940.0K
5 sales by 1 insider
60% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
- 12
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Ciongoli Gregory Austin | $949.4K | — | Aug 27, 2026 |
| PAKOLA STEVE | — | $940.0K | Jul 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Chan Mitchell Chief Financial Officer | Tax withheld | 4,902 | $45.7K |
| Sep 1, 2026 | Malzahn Craig Chief Technology Officer | Tax withheld | 234 | $2.2K |
| Aug 27, 2026 | Ciongoli Gregory Austin Director | Purchase | 53,407 | $499.7K |
| Aug 26, 2026 | Ciongoli Gregory Austin Director | Purchase | 49,196 | $449.7K |
| Aug 25, 2026 | Ciongoli Gregory Austin Director | Award | 15,432 | $0 |
| Aug 1, 2026 | PAKOLA STEVE Chief Medical Officer | Tax withheld | 7,468 | $72.4K |
| Aug 1, 2026 | Christmas Patrick J. Chief Strategy & Legal Officer | Tax withheld | 4,699 | $45.5K |
| Jul 2, 2026 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 plan | 2,161 | $29.5K |
| Jul 2, 2026 | PAKOLA STEVE Chief Medical Officer | Option exercise 10b5-1 plan | 2,161 | $17.0K |
| Jul 1, 2026 | Simpson Curran Chief Executive Officer | Tax withheld | 6,818 | $89.2K |
| Jul 1, 2026 | PAKOLA STEVE Chief Medical Officer | Option exercise | 36,725 | $288.7K |
| Jul 1, 2026 | PAKOLA STEVE Chief Medical Officer | Sale | 36,725 | $472.3K |
| Jun 30, 2026 | Simpson Curran Chief Executive Officer | Award | 1,453 | $14.8K |
| Jun 29, 2026 | PAKOLA STEVE Chief Medical Officer | Sale | 19,608 | $216.5K |
| May 29, 2026 | Mills Kenneth T. Director | Award | 9,807 | $0 |
| May 29, 2026 | Fox Allan M. Director | Award | 9,807 | $0 |
| May 29, 2026 | Glucksmann Alexandra Director | Award | 9,807 | $0 |
| May 29, 2026 | Zachary Jennifer Director | Award | 9,807 | $0 |
| May 29, 2026 | Bennett Jean Director | Award | 9,807 | $0 |
| May 29, 2026 | KARABELAS ARGERIS N Director | Award | 9,807 | $0 |
| May 29, 2026 | MIGAUSKY GEORGE V Director | Award | 9,807 | $0 |
| May 29, 2026 | Tasse Daniel Director | Award | 9,807 | $0 |
| May 29, 2026 | STUMP DAVID C Director | Award | 9,807 | $0 |
| May 11, 2026 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 plan | 15,309 | $168.7K |
| Mar 10, 2026 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 plan | 5,124 | $53.0K |
| Feb 1, 2026 | Christmas Patrick J. Chief Strategy & Legal Officer | Tax withheld | 4,700 | $52.5K |
| Feb 1, 2026 | PAKOLA STEVE Chief Medical Officer | Tax withheld | 5,267 | $58.8K |
| Jan 27, 2026 | Mills Kenneth T. Director | Tax withheld | 221,753 | $2.97M |
| Jan 27, 2026 | Mills Kenneth T. Director | Option exercise | 225,000 | $2.95M |
| Jan 6, 2026 | Malzahn Craig Chief Technology Officer | Award | 65,847 | $0 |
| Jan 6, 2026 | Simpson Curran Chief Executive Officer | Award | 144,864 | $0 |
| Jan 6, 2026 | Chan Mitchell Chief Financial Officer | Award | 73,749 | $0 |
| Jan 6, 2026 | PAKOLA STEVE Chief Medical Officer | Award | 65,847 | $0 |
| Jan 6, 2026 | Christmas Patrick J. Chief Strategy & Legal Officer | Award | 73,749 | $0 |
| Jan 2, 2026 | Simpson Curran Chief Executive Officer | Tax withheld | 18,559 | $267.2K |
| Jan 2, 2026 | Christmas Patrick J. Chief Strategy & Legal Officer | Tax withheld | 9,793 | $141.0K |
| Jan 2, 2026 | PAKOLA STEVE Chief Medical Officer | Tax withheld | 18,247 | $262.8K |
| Jan 2, 2026 | Malzahn Craig Chief Technology Officer | Tax withheld | 1,238 | $17.8K |
| Dec 31, 2025 | Simpson Curran Chief Executive Officer | Award | 951 | $6.7K |
| Oct 9, 2025 | Simpson Curran Chief Executive Officer | Sale 10b5-1 plan | 20,811 | $262.6K |
| Sep 29, 2025 | Simpson Curran Chief Executive Officer | Sale 10b5-1 plan | 7,624 | $76.5K |
| Sep 10, 2025 | Simpson Curran Chief Executive Officer | Sale 10b5-1 plan | 7,734 | $77.5K |
| Sep 1, 2025 | Chan Mitchell Chief Financial Officer | Tax withheld | 4,901 | $43.8K |
| Sep 1, 2025 | Malzahn Craig Chief Technology Officer | Tax withheld | 234 | $2.1K |
| Aug 1, 2025 | Christmas Patrick J. Chief Strategy & Legal Officer | Tax withheld | 4,699 | $38.5K |
| Jul 1, 2025 | Simpson Curran Chief Executive Officer | Tax withheld | 4,701 | $38.7K |
| May 30, 2025 | Glucksmann Alexandra Director | Award | 7,768 | $0 |
| May 30, 2025 | MIGAUSKY GEORGE V Director | Award | 7,768 | $0 |
| May 30, 2025 | Mills Kenneth T. Director | Award | 7,768 | $0 |
| May 30, 2025 | STUMP DAVID C Director | Award | 7,768 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for REGENXBIO Inc.
Free account. Everything above stays public.
Write why you follow REGENXBIO Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading